[The natural history of multiple sclerosis]

Christian Confavreux1, Sandra Vukusic

  • 1Service de neurologie A, centre de coordination Edmus et Inserm U433, hôpital neurologique Pierre-Wertheimer, 69677 Lyon, Bron. christian.confavreux@chu-lyon.fr

La Revue Du Praticien
|September 5, 2006
PubMed

Insights

Multiple sclerosis (MS) prognosis is highly variable, with progression, not relapses, significantly impacting irreversible neurological disability accumulation. Understanding MS complexity is key despite its heterogeneity.

Area of Science:

  • Neurology
  • Clinical Neuroscience

Context:

  • Multiple sclerosis (MS) is characterized by relapses and progression, with three main clinical forms: relapsing-remitting, secondary progressive, and primary progressive.
  • The disease typically manifests around age 30, affecting 85% of patients with a remitting course and 15% with a progressive course.
  • Initial symptoms often involve disturbances in the central nervous system's long tracts, brainstem, or optic nerve.

Purpose:

  • To analyze the interplay of relapses and progression in multiple sclerosis (MS) and their impact on disease course and prognosis.
  • To evaluate the effectiveness of clinical and paraclinical factors in predicting individual MS prognosis.
  • To explore a unifying concept for understanding the complexity and heterogeneity of MS.

Summary:

  • MS prognosis is highly variable, ranging from benign to malignant forms, with significant individual differences.
  • Progression, rather than relapses, is the primary driver of irreversible neurological disability accumulation in MS.
  • The age at which irreversible disability landmarks are reached is similar regardless of the initial disease onset (relapsing-remitting or progressive).

Impact:

  • Highlights that clinical and paraclinical predictive factors offer limited individual prognostic value in MS.
  • Suggests that focusing on progression, rather than just relapses, is crucial for understanding MS disability.
  • Proposes a unifying concept of "complexity vs heterogeneity" to conceptualize the diverse clinical presentations of MS.